Clinical Trial

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07487948
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: LEO Pharma
Conditions Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Enrollment 30 participants
Start Date 2026-05-19
Primary Completion 2027-04-05 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10